-- Announcement on Progress in Providing Guarantee for Holding Subsidiary
Securities code: 603739 Securities abbreviation: Weilan Biotechnology Announcement number: 2025-042
Qingdao Weilan Biological Co., Ltd.
Announcement on the progress of providing guarantees for holding subsidiaries
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.
or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.
Important content reminder:
Guaranteed objects and basic information
Name of guaranteed person Qingdao Kangdien Animal Pharmaceutical Co., Ltd.
The amount of this guarantee is RMB 30 million
Guarantee Object 1 The actual guarantee balance provided for it is RMB 66.5481 million
Is it within the pre-estimated amount? Yes □No □Not applicable: _________Whether there is a counter-guarantee for this guarantee □Yes No □Not applicable: _________Name of the guaranteed person Qingdao Weilan Biological Group Co., Ltd.
The guarantee amount is RMB 50 million
Guarantee Object 2 The actual guarantee balance provided for it is RMB 195.9715 million
Is it within the pre-expected amount? Yes □No □Not applicable: _________Is there a counter-guarantee for this guarantee? □Yes No □Not applicable: _________Name of the guaranteed person Qingdao Master Biotechnology Co., Ltd.
The guarantee amount is 5.70 million yuan
Guarantee Object 3 The actual guarantee balance provided for it is RMB 0,000
Is it within the pre-expected amount? Yes □No □Not applicable: _________Is there a counter-guarantee for this guarantee? □Yes No □Not applicable: _________
Cumulative guarantee status
Cumulative amount of overdue external guarantees (10,000 yuan) 0.00
Listed companies and their holdings as of the date of this announcement
112,320.00
Total external guarantees provided by subsidiaries (10,000 yuan)
The total amount of external guarantees accounted for the most recent period for listed companies.
64.64%
Proportion of audited net assets for the period (%)
The total amount of external guarantees (including this one) exceeds 50% of the listed company’s latest audited net assets
□The total amount of external guarantees (including this time) exceeds 100% of the listed company’s latest special risk reminder (if any, please check) the first-phase audited net assets
□The total amount of guarantees for units outside the consolidated statements (including this time) reaches or exceeds 30% of the latest audited net assets
□ This time, guarantees will be provided to units whose asset-liability ratio exceeds 70%. Other risk reminders (if any) None
1. Overview of guarantee situation
(1) Basic information on guarantee
On September 28, 2025, Qingdao Weilan Biotechnology Co., Ltd. (hereinafter referred to as the "Company") and Hua Xia Bank Co., Ltd. Qingdao Hong Kong Middle Road Branch signed the "Maximum Guarantee Contract" to provide joint liability guarantee for the credit business carried out by the company's wholly-owned subsidiary Qingdao Condien Animal Pharmaceutical Co., Ltd. (hereinafter referred to as "Animal Pharmaceutical") with the bank, with a total guarantee of RMB 30 million.
On September 29, 2025, the company signed a "Guarantee Contract" with the Qingdao Olympic Sailing Branch of the Industrial and Commercial Bank of China Co., Ltd. to provide a joint liability guarantee for the credit business carried out by the company's wholly-owned subsidiary Qingdao Weilan Biological Group Co., Ltd. (hereinafter referred to as "Weilan Biological Group") with the bank, with a total guarantee of RMB 50 million.
On September 29, 2025, the company signed the "Maximum Guarantee Contract" with the Qingdao Chengyang Branch of China Everbright Bank Co., Ltd. to provide joint liability guarantee for the credit business carried out by the company's controlled subsidiary Qingdao Master Biotechnology Co., Ltd. (hereinafter referred to as "Master") with the bank, with a total guarantee of RMB 5.70 million. Minority shareholders Yu Weizhen, Qingdao Shunrong Biotechnology Co., Ltd., Wei Wanquan, and Xu Wei provided guarantees in the same proportion as their equity holdings in Master.
(2) Internal decision-making procedures
The above guarantee matters have been reviewed and approved by the company at the 16th meeting of the fifth board of directors held on April 25, 2025, and approved by the company's 2024 annual shareholders' meeting held on May 16, 2025. For details, please refer to the "Announcement of Qingdao Weilan Biotechnology Co., Ltd. on the Estimated External Guarantee Amount for 2025" (Announcement Number: 2025-011) and the "Announcement on the Resolution of the 2024 Annual Shareholders Meeting of Qingdao Weilan Biotechnology Co., Ltd." (Announcement Number: 2025-022) disclosed by the company on the Shanghai Stock Exchange website on April 26, 2025 and May 17, 2025 respectively.
2. Basic information of the guaranteed person
(1) Basic situation of animal pharmaceutical industry
Legal person
Guaranteed person type
□Other______________ (please specify)
Name of guaranteed person Qingdao Kangdien Animal Pharmaceutical Co., Ltd.
Wholly owned subsidiary
Type of guaranteed party and listed company □Holding subsidiary
Shareholding status of the company □Share-joining companies
□Other______________ (please specify)
Major shareholders and shareholding ratios of Qingdao Weilan Animal Health Group Co., Ltd., a wholly-owned subsidiary of the company
100% equity of Wu Pharmaceutical Industry
Legal representative Liu Xifeng
Unified social credit code 91370214737278437X
Established on June 17, 2002
Registration address: No. 85, Keyun Road, High-tech Zone, Qingdao City, Shandong Province
Registered capital RMB 100 million
Company type: Limited liability company (a sole proprietorship of a legal person invested or controlled by a natural person) Licensed projects: veterinary drug production; feed additive production; veterinary drug operation; feed production. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: pet food and supplies wholesale; technical service business scope
services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of special chemical products (excluding hazardous chemicals); sales of feed raw materials; sales of specialized veterinary equipment; import and export of goods. (Except for projects that require approval according to law, business activities can be carried out independently in accordance with the law with a business license) June 30, 2025
Project December 31, 2024/January-June 2025 (not yet
/2024 (audited)
audited)
Total assets 34,223.84 28,000.68Main financial indicators (10,000 yuan)
Total liabilities 23,099.33 18,906.33Net assets 11,124.51 9,094.35Operating income 6,251.84 13,680.10Net profit -469.84 -342.46
(2) Basic information of Weilan Biotech Group
Legal person
Guaranteed person type
□Other______________ (please specify)
Name of the guaranteed party Qingdao Weilan Biological Group Co., Ltd.
Wholly owned subsidiary
Type of guaranteed party and listed company □Holding subsidiary
Shareholding status of the company □Share-joining companies
□Other______________ (please specify)
Major shareholders and shareholding ratio: The company holds 100% equity of Weilan Biotech Group
Legal representative Chen Gang
Unified social credit code 91370212664526566H
Established on August 22, 2007
Registration address: Industrial Park, No. 596-1, Jiushui East Road, Laoshan District, Qingdao City, Shandong Province
Registered capital RMB 20 million
Company type Limited liability company (a sole proprietorship of a legal person invested or controlled by a natural person)
Licensed items: import and export of goods; import and export of technology; food business (sales of pre-packaged food); catering services; Internet sales of food; Internet sales of food (sale of pre-packaged food); food business; sales of health food; sales of formula foods for special medical purposes; business of veterinary drugs. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: bio-based material technology research and development; industrial enzyme preparation research and development; biomass liquid fuel business scope Research and development of feed production technology; research and development of biological feed; research and development of bio-organic fertilizer; research and development of fermentation process optimization technology; research and development of biochemical product technology; research and development of extraction, purification and synthesis technology of marine biological active substances; research and development and application of cell technology; technical services, technology development, technical consultation, technical exchange, technology Technology transfer and promotion; food additive sales; investment activities with own funds; livestock and fishery feed sales; feed raw material sales; feed additive sales; business management; property management; conference and exhibition services; Internet sales (except for the sale of goods requiring licenses); cosmetics wholesale; cosmetics retail sales; sales of sanitary products and disposable medical supplies; sales of personal hygiene products; sales of daily necessities; wholesale of daily necessities; sales of daily groceries; wholesale of pet food and supplies; retail of pet food and supplies; information consulting services (excluding licensed information consulting services); information technology consulting services; health consulting Consulting services (excluding diagnostic and treatment services); development of human genetic diagnosis and treatment technology; sales of chemical products (excluding licensed chemical products); sales of Class I medical devices; sales of disinfectants (excluding hazardous chemicals); business management consulting; and educational consulting services (excluding education and training activities involving licensing approval). (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
June 30, 2025
Project December 31, 2024/January-June 2025 (not yet
/2024 (audited)
audited)
Total assets 201,186.95 190,933.03
Main financial indicators (10,000 yuan)
Total liabilities 120,037.81 114,773.34
Net assets 81,149.14 76,159.69
Operating income 47,732.06 86,112.37
Net profit 6,578.12 13,299.33
(3) Basic information of Master
Legal person
Guaranteed person type
□Other______________ (please specify)
Name of guaranteed person Qingdao Master Biotechnology Co., Ltd.
□Wholly owned subsidiary
Type of guaranteed party and listed company Holding subsidiaries
Shareholding status of the company □Share-joining companies
□Other______________ (please specify)
Major shareholders and shareholding ratios: Weilan Biotech Group, a wholly-owned subsidiary of the company, holds 57.00% of Master’s equity. Legal representative Wei Wanquan
Unified social credit code 91370281737298796J
Established on June 17, 2002
Registration address: No. 11, Xindong Road, Jiulong Street Office, Jiaozhou City, Qingdao City
Registered capital RMB 13 million
Company Type Other Limited Liability Company
Licensed projects: feed additive production; feed production. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: biological feed research and development; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; engineering and technology research and test development business scope Exhibition; research and development of extraction, purification and synthesis technology of marine biological active substances; information technology consulting services; information consulting services (excluding licensing information consulting services); feed additive sales; non-edible salt processing; non-edible salt sales; eco-environmental material manufacturing; eco-environmental material sales; import and export of goods; import and export of technology. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
June 30, 2025
Project December 31, 2024/January-June 2025 (not yet
/2024 (audited)
audited)
Total assets 9,593.20 9,813.52
Main financial indicators (10,000 yuan)
Total liabilities 1,962.98 1,679.24
Net assets 7,630.22 8,134.28
Operating income 3,115.11 5,173.26
Net profit 495.95 886.35
3. Main contents of the guarantee agreement
(1) Animal medicine industry
Creditor: Qingdao Hong Kong Middle Road Branch of Hua Xia Bank Co., Ltd.
Debtor: Qingdao Kangdien Animal Pharmaceutical Co., Ltd.
Guarantor: Qingdao Weilan Biological Co., Ltd.
Guarantee method: joint liability guarantee
Guarantee amount: RMB 30 million
Guarantee period: three years
Guarantee scope: principal of the main creditor's right, interest, overdue interest, penalty interest, compound interest, liquidated damages, damages, exchange rate losses (related losses caused by exchange rate changes), as well as appraisal fees, appraisal fees, auction fees, litigation fees, arbitration fees, notary fees, attorney fees and other reasonable expenses incurred by Party B to realize the creditor's rights, as well as the expenses payable by all other main contract debtors.
(2) Azure Biotech Group
Creditor: Industrial and Commercial Bank of China Co., Ltd. Qingdao Olympic Sailing Branch
Debtor: Qingdao Weilan Biological Group Co., Ltd.
Guarantor: Qingdao Weilan Biological Co., Ltd.
Guarantee method: joint liability guarantee
Guarantee amount: RMB 50 million
Guarantee period: three years from the day after the expiration of the loan period or precious metal lease period under the main contract; if the creditor declares the early expiration of the loan or precious metal lease in accordance with the provisions of the main contract, the guarantee period is three years from the day after the early expiration date of the loan or precious metal lease.
Guarantee scope: principal of the main claim (including the principal of the precious metal lease claim and the RMB amount converted according to the precious metal lease contract), interest, precious metal lease fees and personalized service fees, compound interest, penalty interest, liquidated damages, damages, precious metal lease weight overage and shortfall fees, Exchange rate losses (related losses caused by changes in exchange rates), related losses caused by changes in precious metal prices, transaction fees and other expenses incurred when the lender of the precious metal leasing contract exercises corresponding rights in accordance with the main contract, and expenses for realizing creditor's rights (including but not limited to litigation fees, attorney fees, etc.).
(3) Master
Creditor: Qingdao Chengyang Branch of China Everbright Bank Co., Ltd.
Debtor: Qingdao Master Biotechnology Co., Ltd.
Guarantor: Qingdao Weilan Biological Co., Ltd.
Guarantee method: joint liability guarantee guarantee
Guarantee amount: RMB 5.70 million
Guarantee period: three years from the expiration date of the fiduciary's debt performance period specified in the specific credit business contract or agreement.
Scope of guarantee: The creditee shall repay or pay to the credit grantor the debt principal, interest (including legal interest, agreed interest and penalty interest), compound interest, liquidated damages, damages, costs for realizing creditor's rights (including but not limited to litigation/arbitration costs, lawyer fees, notarization fees, execution costs, etc.) and all other payable fees.
4. Necessity and Reasonability of Guarantee
This guarantee is to meet the business development and production and operation needs of the company and its holding subsidiaries, and is in line with the company's overall interests and development strategy. The guaranteed parties are all holding subsidiaries with an asset-liability ratio of less than 70%. The company can effectively control the risks and decisions of daily operating activities of its holding subsidiaries, and there is no harm to the interests of the company and shareholders.
5. Opinions of the Board of Directors
The company held the 16th meeting of the fifth board of directors on April 25, 2025, and reviewed and approved the "Proposal on Applying for Bank Credit Lines and Providing Guarantees". For details, please refer to the "Announcement on the Estimated External Guarantee Line in 2025" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on April 26, 2025 (Announcement Number: 2025-011).
This guarantee matter is within the scope of the above-mentioned review by the board of directors, and there is no need to convene a separate meeting of the board of directors for review.
6. Cumulative number of external guarantees and number of overdue guarantees
(1) Cumulative amount of external guarantees
As of the date of this announcement, the total external guarantees provided by the company and its holding subsidiaries are RMB 1,123.20 million, accounting for 64.64% of the company's audited net assets attributable to shareholders of listed companies on December 31, 2024. Among them, the company's total guarantees for its holding subsidiaries are 1,123.20 million yuan, accounting for 64.64% of the company's audited net assets attributable to shareholders of listed companies on December 31, 2024.
(2) Overdue guarantee
As of the date of this announcement, the company has no overdue guarantees.
Announcement is hereby made.
Board of Directors of Qingdao Weilan Biological Co., Ltd.
September 30, 2025